U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H26ClN3OS
Molecular Weight 403.9705
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PERPHENAZINE

SMILES

c1ccc2c(c1)N(CCCN3CCN(CC3)CCO)c4cc(ccc4S2)Cl

InChI

InChIKey=RGCVKNLCSQQDEP-UHFFFAOYSA-N
InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2

HIDE SMILES / InChI
Perphenazine is a relatively high potency phenothiazine that blocks dopamine 2 receptors predominantly, but also may possess antagonist actions at histamine 1 and cholinergic M1 and alpha 1 adrenergic receptors in the vomiting center leading to reduced nausea and vomiting. The drug was approved by FDA for the treatment of schizophrenia and control of severe nausea and vomiting (either alone or in combination with amitriptyline hydrochloride). Perphenazine is extensively hepatic to metabolites via sulfoxidation, hydroxylation, dealkylation, and glucuronidation; primarily metabolized by CYP2D6 to N-dealkylated perphenazine, perphenazine sulfoxide, and 7-hydroxyperphenazine (active metabolite with 70% of the activity of perphenazine) and excreted in the urine and feces.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P14416
Gene ID: 1813
Gene Symbol: DRD2
Target Organism: Homo sapiens (Human)
0.160000000000000003 nM [Ki]
Target ID: P35367
Gene ID: 3269
Gene Symbol: HRH1
Target Organism: Homo sapiens (Human)
8 nM [Kd]
Target ID: P11229
Gene ID: 1128
Gene Symbol: CHRM1
Target Organism: Homo sapiens (Human)
1.5 µM [Kd]
10 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
PERPHENAZINE

Approved Use

Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults.

Launch Date

587347200000
Preventing
PERPHENAZINE

Approved Use

Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults.

Launch Date

587347200000
Primary
PERPHENAZINE

Approved Use

Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults.

Launch Date

587347200000
Primary
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

Approved Use

Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate.

Launch Date

595123200000
Primary
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

Approved Use

Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate.

Launch Date

595123200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
509 pg/mL
4 mg 3 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
7-HYDROXYPERPHENAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
0.546 ng/mL
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PERPHENAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
984 pg/mL
4 mg 3 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERPHENAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.673 ng × h/mL
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PERPHENAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
18.8 h
4 mg 3 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
7-HYDROXYPERPHENAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
9.12 h
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PERPHENAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
12 h
4 mg 3 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERPHENAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
9%
unknown, unknown
PERPHENAZINE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.93 g single, oral
Overdose
dose: 0.93 g
route: oral
experiment_type: single
dose_type: Overdose
co-adm with
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/21264008
    unhealthy, 42
    population: unhealthy
    age: 42
    sex: M
    food_status:
    n:
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/21264008
    Disc. AE: QT interval prolonged, Hypothermia...
    AEs leading to
    discontinuation/dose reduction:​
    QT interval prolonged
    Hypothermia
    Loss of consciousness
    PR interval prolonged
    QRS prolonged

    data_source:
    https://pubmed.ncbi.nlm.nih.gov/21264008
    200 mg single, oral
    Overdose
    dose: 200 mg
    route: oral
    experiment_type: single
    dose_type: Overdose
    co-adm with
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/1729053
      unhealthy, 48
      population: unhealthy
      age: 48
      sex: F
      food_status:
      n:
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/1729053
      Disc. AE: Coma, Hypothermia...
      AEs leading to
      discontinuation/dose reduction:​
      Coma
      Hypothermia
      Tachycardia
      Miosis

      data_source:
      https://pubmed.ncbi.nlm.nih.gov/1729053
      30 mg 1 times / day multiple, intramuscular
      Recommended
      dose: 30 mg 1 times / day
      route: intramuscular
      experiment_type: multiple
      dose_type: Recommended
      co-adm with
        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
        unhealthy
        population: unhealthy
        age:
        sex:
        food_status:
        n:
        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
        Disc. AE: Neuroleptic malignant syndrome...
        AEs leading to
        discontinuation/dose reduction:​
        Neuroleptic malignant syndrome

        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
        30 mg 1 times / day multiple, intramuscular
        Recommended
        dose: 30 mg 1 times / day
        route: intramuscular
        experiment_type: multiple
        dose_type: Recommended
        co-adm with
          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
          unhealthy
          population: unhealthy
          age:
          sex:
          food_status:
          n:
          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
          Disc. AE: Tardive dyskinesia...
          AEs leading to
          discontinuation/dose reduction:​
          Tardive dyskinesia

          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
          64 mg 1 times / day multiple, oral
          Recommended
          dose: 64 mg 1 times / day
          route: oral
          experiment_type: multiple
          dose_type: Recommended
          co-adm with
            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
            unhealthy
            population: unhealthy
            age:
            sex:
            food_status:
            n:
            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
            Disc. AE: Neuroleptic malignant syndrome...
            AEs leading to
            discontinuation/dose reduction:​
            Neuroleptic malignant syndrome

            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
            64 mg 1 times / day multiple, oral
            Recommended
            dose: 64 mg 1 times / day
            route: oral
            experiment_type: multiple
            dose_type: Recommended
            co-adm with
              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
              unhealthy
              population: unhealthy
              age:
              sex:
              food_status:
              n:
              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
              Disc. AE: Tardive dyskinesia...
              AEs leading to
              discontinuation/dose reduction:​
              Tardive dyskinesia

              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
              20 mg single, intramuscular
              Studied dose
              dose: 20 mg
              route: intramuscular
              experiment_type: single
              dose_type: Studied dose
              co-adm with
                data_source:
                https://pubmed.ncbi.nlm.nih.gov/3588517/
                unhealthy
                population: unhealthy
                age:
                sex:
                food_status:
                n:
                data_source:
                https://pubmed.ncbi.nlm.nih.gov/3588517/
                Disc. AE: Neuroleptic malignant syndrome...
                AEs leading to
                discontinuation/dose reduction:​
                Neuroleptic malignant syndrome

                data_source:
                https://pubmed.ncbi.nlm.nih.gov/3588517/
                AEs

                AEs

                AESignificanceDosePopulation
                Hypothermia
                Disc. AE
                0.93 g single, oral
                Overdose
                dose: 0.93 g
                route: oral
                experiment_type: single
                dose_type: Overdose
                co-adm with
                  data_source:
                  https://pubmed.ncbi.nlm.nih.gov/21264008
                  unhealthy, 42
                  population:
                  age:
                  sex:
                  food_status:
                  n:
                  data_source:
                  https://pubmed.ncbi.nlm.nih.gov/21264008
                  Loss of consciousness
                  Disc. AE
                  0.93 g single, oral
                  Overdose
                  dose: 0.93 g
                  route: oral
                  experiment_type: single
                  dose_type: Overdose
                  co-adm with
                    data_source:
                    https://pubmed.ncbi.nlm.nih.gov/21264008
                    unhealthy, 42
                    population:
                    age:
                    sex:
                    food_status:
                    n:
                    data_source:
                    https://pubmed.ncbi.nlm.nih.gov/21264008
                    PR interval prolonged
                    Disc. AE
                    0.93 g single, oral
                    Overdose
                    dose: 0.93 g
                    route: oral
                    experiment_type: single
                    dose_type: Overdose
                    co-adm with
                      data_source:
                      https://pubmed.ncbi.nlm.nih.gov/21264008
                      unhealthy, 42
                      population:
                      age:
                      sex:
                      food_status:
                      n:
                      data_source:
                      https://pubmed.ncbi.nlm.nih.gov/21264008
                      QRS prolonged
                      Disc. AE
                      0.93 g single, oral
                      Overdose
                      dose: 0.93 g
                      route: oral
                      experiment_type: single
                      dose_type: Overdose
                      co-adm with
                        data_source:
                        https://pubmed.ncbi.nlm.nih.gov/21264008
                        unhealthy, 42
                        population:
                        age:
                        sex:
                        food_status:
                        n:
                        data_source:
                        https://pubmed.ncbi.nlm.nih.gov/21264008
                        QT interval prolonged
                        Disc. AE
                        0.93 g single, oral
                        Overdose
                        dose: 0.93 g
                        route: oral
                        experiment_type: single
                        dose_type: Overdose
                        co-adm with
                          data_source:
                          https://pubmed.ncbi.nlm.nih.gov/21264008
                          unhealthy, 42
                          population:
                          age:
                          sex:
                          food_status:
                          n:
                          data_source:
                          https://pubmed.ncbi.nlm.nih.gov/21264008
                          Neuroleptic malignant syndrome
                          Disc. AE
                          20 mg single, intramuscular
                          Studied dose
                          dose: 20 mg
                          route: intramuscular
                          experiment_type: single
                          dose_type: Studied dose
                          co-adm with
                            data_source:
                            https://pubmed.ncbi.nlm.nih.gov/3588517/
                            unhealthy
                            population:
                            age:
                            sex:
                            food_status:
                            n:
                            data_source:
                            https://pubmed.ncbi.nlm.nih.gov/3588517/
                            Coma
                            Disc. AE
                            200 mg single, oral
                            Overdose
                            dose: 200 mg
                            route: oral
                            experiment_type: single
                            dose_type: Overdose
                            co-adm with
                              data_source:
                              https://pubmed.ncbi.nlm.nih.gov/1729053
                              unhealthy, 48
                              population:
                              age:
                              sex:
                              food_status:
                              n:
                              data_source:
                              https://pubmed.ncbi.nlm.nih.gov/1729053
                              Hypothermia
                              Disc. AE
                              200 mg single, oral
                              Overdose
                              dose: 200 mg
                              route: oral
                              experiment_type: single
                              dose_type: Overdose
                              co-adm with
                                data_source:
                                https://pubmed.ncbi.nlm.nih.gov/1729053
                                unhealthy, 48
                                population:
                                age:
                                sex:
                                food_status:
                                n:
                                data_source:
                                https://pubmed.ncbi.nlm.nih.gov/1729053
                                Miosis
                                Disc. AE
                                200 mg single, oral
                                Overdose
                                dose: 200 mg
                                route: oral
                                experiment_type: single
                                dose_type: Overdose
                                co-adm with
                                  data_source:
                                  https://pubmed.ncbi.nlm.nih.gov/1729053
                                  unhealthy, 48
                                  population:
                                  age:
                                  sex:
                                  food_status:
                                  n:
                                  data_source:
                                  https://pubmed.ncbi.nlm.nih.gov/1729053
                                  Tachycardia
                                  Disc. AE
                                  200 mg single, oral
                                  Overdose
                                  dose: 200 mg
                                  route: oral
                                  experiment_type: single
                                  dose_type: Overdose
                                  co-adm with
                                    data_source:
                                    https://pubmed.ncbi.nlm.nih.gov/1729053
                                    unhealthy, 48
                                    population:
                                    age:
                                    sex:
                                    food_status:
                                    n:
                                    data_source:
                                    https://pubmed.ncbi.nlm.nih.gov/1729053
                                    Neuroleptic malignant syndrome
                                    Disc. AE
                                    30 mg 1 times / day multiple, intramuscular
                                    Recommended
                                    dose: 30 mg 1 times / day
                                    route: intramuscular
                                    experiment_type: multiple
                                    dose_type: Recommended
                                    co-adm with
                                      data_source:
                                      https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
                                      unhealthy
                                      Tardive dyskinesia
                                      Disc. AE
                                      30 mg 1 times / day multiple, intramuscular
                                      Recommended
                                      dose: 30 mg 1 times / day
                                      route: intramuscular
                                      experiment_type: multiple
                                      dose_type: Recommended
                                      co-adm with
                                        data_source:
                                        https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
                                        unhealthy
                                        Neuroleptic malignant syndrome
                                        Disc. AE
                                        64 mg 1 times / day multiple, oral
                                        Recommended
                                        dose: 64 mg 1 times / day
                                        route: oral
                                        experiment_type: multiple
                                        dose_type: Recommended
                                        co-adm with
                                          data_source:
                                          https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
                                          unhealthy
                                          Tardive dyskinesia
                                          Disc. AE
                                          64 mg 1 times / day multiple, oral
                                          Recommended
                                          dose: 64 mg 1 times / day
                                          route: oral
                                          experiment_type: multiple
                                          dose_type: Recommended
                                          co-adm with
                                            data_source:
                                            https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
                                            unhealthy
                                            Overview

                                            Overview

                                            Drug as perpetrator​Drug as victimTox targets

                                            Tox targets

                                            PubMed

                                            PubMed

                                            TitleDatePubMed
                                            The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.
                                            1967
                                            Side-effects of phenothiazines.
                                            1967 Apr 1
                                            Phenothiazines in early labour.
                                            1967 Feb 11
                                            Drug-induced extrapyramidal symptoms: their incidence and treatment.
                                            1967 Jan
                                            Oculogyric crises due to phenothiazines.
                                            1967 Jul 22
                                            Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients.
                                            1967 Mar-Apr
                                            Phenothiazines and diabetes in hospitalized women.
                                            1968 Jan
                                            Dystonic reaction to perphenazine.
                                            1969 Aug 9
                                            Perphenazine dystonia presenting as recurrent dislocation of the jaw.
                                            1969 Jan
                                            Iatrogenic epilepsy due to antidepressant drugs.
                                            1969 Oct 11
                                            Increased sensitivity to neuroleptics in rats with lesions of the central nervous system.
                                            1972
                                            Idiosyncratic responses to phenothiazines.
                                            1972 Jan 22
                                            The mechanism of the potentiating effect of antidepressant drugs on the protective influenc oe of diphenhydramine in experimental catatonia. The role of histamine.
                                            1974
                                            Letter: Side-effects of perphenazine.
                                            1975 Jun 21
                                            Asymptomatic idiopathic syndrome of prolonged Q-T interval in a 45-year-old woman. Ventricular tachyarrhythmias precipitated by hypokalemia and therapy with amitriptyline and prephenazine.
                                            1977 Feb
                                            Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms.
                                            1977 Mar 12
                                            [Acute dystonia in children. 2 cases caused by perphenazine (Trilafon)].
                                            1978 Mar 10
                                            Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule.
                                            1978 Oct 7
                                            Electrophysiologic studies of perphenazine and protriptyline in a patient with psychotropic drug-induced ventricular fibrillation.
                                            1979 Aug
                                            Seven cases of somnambulism induced by drugs.
                                            1979 Jul
                                            Metoclopramide and dystonic reactions in Sardinians.
                                            1979 Jun 23
                                            Toxic psychosis with cimetidine.
                                            1979 May
                                            Pituitary sensitivity to LHRH in hyperprolactinemia induced by perphenazine and renal pituitary transplants in female rats.
                                            1980 Apr
                                            Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.
                                            1981
                                            Actions of clonidine on convulsions and behaviour.
                                            1981 Jul
                                            Prolactin and the small intestine. Effect of hyperprolactinaemia on mucosal structure in the rat.
                                            1981 Jul
                                            Tricyclic antidepressants and alcoholic blackouts.
                                            1981 Jun
                                            Dose-response relationships of perphenazine in the treatment of acute psychoses.
                                            1982
                                            Cerebellar syndrome following neuroleptic induced heat stroke.
                                            1983 Feb
                                            Unique sensitivity of Hb Zürich to oxidative injury by phenazopyridine: reversal of the effects by elevating carboxyhemoglobin levels in vivo and in vitro.
                                            1983 Jun
                                            Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes.
                                            1984 Sep
                                            Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain.
                                            1985 Apr
                                            GABAergic, dopaminergic and cholinergic interactions in perphenazine-induced catatonia in rats.
                                            1985 Dec
                                            Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
                                            1986
                                            A case of progressive hemichorea responsive to high-dose reserpine.
                                            1986 Mar
                                            Tourette-like syndrome following low dose short-term neuroleptic treatment.
                                            1986 May
                                            L-tryptophan in drug-induced movement disorders with insomnia.
                                            1986 May 8
                                            Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study.
                                            1987 Jul
                                            Neuroleptic malignant syndrome during perphenazine treatment.
                                            1987 Mar
                                            The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
                                            1990 Aug
                                            Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.
                                            1993 Dec
                                            Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.
                                            1994 Mar
                                            The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery.
                                            1995 Jul
                                            BMY-14802 reversed the sigma receptor agonist-induced neck dystonia in rats.
                                            1996
                                            Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report.
                                            1997 Dec 1
                                            Induction of mania by risperidone resistant to mood stabilizers.
                                            1997 Feb
                                            Olanzapine use in women with antipsychotic-induced hyperprolactinemia.
                                            1998 Oct
                                            Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
                                            2011 Jul 14
                                            Antitubercular pharmacodynamics of phenothiazines.
                                            2013 Apr
                                            Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine.
                                            2014 Jun
                                            Patents

                                            Sample Use Guides

                                            Moderately disturbed nonhospitalized patients with schizophrenia: 4 to 8 mg t.i.d. initially; reduce as soon as possible to minimum effective dosage. Hospitalized patients with schizophrenia: 8 to 16 mg b.i.d. to q.i.d.; avoid dosages in excess of 64 mg daily. Severe nausea and vomiting in adults: 8 to 16 mg daily in divided doses; 24 mg occasionally may be necessary; early dosage reduction is desirable.
                                            Route of Administration: Oral
                                            Perphenazine (10-100 microM) was administered, either alone or combined with dopamine, to primary mouse neuronal or intact brain culture and to a human neuroblastoma (NB) cell line (SK-N-SH). Cell viability (measured by neutral red and alamar blue), DNA fragmentation (flow cytometry-NB) were determined. Neuroblastoma: perphenazine decreased viability by 87%.
                                            Name Type Language
                                            PERPHENAZINE
                                            EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
                                            INN  
                                            Official Name English
                                            PERPHENAZINE COMPONENT OF ETRAFON-A
                                            Common Name English
                                            PIPERAZINEETHANOL, 4-(3-(2-CHLORO-10H-PHENOTHIAZIN-10-YL)PROPYL)-
                                            Systematic Name English
                                            PERPHENAZINE [HSDB]
                                            Common Name English
                                            4-(3-(2-CHLOROPHENOTHIAZIN-10-YL)PROPYL)-1-PIPERAZINEETHANOL
                                            Systematic Name English
                                            TRILAFON
                                            Brand Name English
                                            PERPHENAZINE [VANDF]
                                            Common Name English
                                            PERPHENAZINE [MART.]
                                            Common Name English
                                            PERPHENAZINE [USP]
                                            Common Name English
                                            PERPHENAZINE MALEATE [JAN]
                                            Common Name English
                                            PERPHENAZINE [JAN]
                                            Common Name English
                                            PERPHENAZINE [WHO-DD]
                                            Common Name English
                                            NSC-150866
                                            Code English
                                            PERPHENAZINE [EP MONOGRAPH]
                                            Common Name English
                                            ETRAFON-A COMPONENT PERPHENAZINE
                                            Common Name English
                                            PERPHENAZINE [INN]
                                            Common Name English
                                            FLUPHENAZINE DIHYDROCHLORIDE IMPURITY E [EP]
                                            Common Name English
                                            PERPHENAZINE [USP-RS]
                                            Common Name English
                                            PERPHENAZINE [ORANGE BOOK]
                                            Common Name English
                                            PERPHENAZINE [MI]
                                            Common Name English
                                            Classification Tree Code System Code
                                            NDF-RT N0000175746
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            WHO-VATC QN05AB03
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            LIVERTOX 764
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            NCI_THESAURUS C29710
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            NDF-RT N0000007544
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            NDF-RT N0000007544
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            NDF-RT N0000007544
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            WHO-ATC N05AB03
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            Code System Code Type Description
                                            RXCUI
                                            8076
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY RxNorm
                                            INN
                                            637
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            EVMPD
                                            SUB09736MIG
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            ChEMBL
                                            CHEMBL567
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            EPA CompTox
                                            58-39-9
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            DRUG BANK
                                            DB00850
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            FDA UNII
                                            FTA7XXY4EZ
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            MESH
                                            D010546
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            WIKIPEDIA
                                            PERPHENAZINE
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            NCI_THESAURUS
                                            C29355
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            DRUG CENTRAL
                                            2113
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            USP_CATALOG
                                            1511000
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY USP-RS
                                            PUBCHEM
                                            4748
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            CAS
                                            58-39-9
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            ECHA (EC/EINECS)
                                            200-381-5
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            MERCK INDEX
                                            M8567
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY Merck Index
                                            HSDB
                                            3379
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            LACTMED
                                            Perphenazine
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY
                                            IUPHAR
                                            209
                                            Created by admin on Fri Jun 25 21:14:55 UTC 2021 , Edited by admin on Fri Jun 25 21:14:55 UTC 2021
                                            PRIMARY